Genmab A/S (CPSE:GMAB) commences share repurchases on March 18, 2024, under the program mandated by the shareholders in the Annual General Meeting held on March 13, 2024. As per the mandate, the company is authorized to repurchase up to a total nominal amount of DKK 3,500,000 own shares, up to 10% of its issued share capital, such that the company?s holding in treasury together with the shares repurchased does not exceed 10% of its issued share capital at any point of time. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on NASDAQ OMX Copenhagen A/S at the time of the acquisition. The repurchase program is intends to primarily use the authorization to enable the company to reduce the dilution effect of the share capital increases resulting from future exercises of warrants. The authorization will be valid till March 12, 2029.

On March 15, 2024, the company announced a share repurchase program. Under the program, the company will repurchase up to DKK 3,500 million worth of shares. Shares acquired under the program cannot be purchased at a price exceeding the higher of the price of the latest independent transaction on Nasdaq Copenhagen and the price of the highest independent bid on Nasdaq Copenhagen at the time of the transaction. The share buy-back program will start on March 18, 2024, and is expected to end no later than December 16, 2024. As of March 14, 2024, the company holds 863,972 treasury shares.